Aptevo Therapeutics Inc. (APVO)
| Market Cap | 10.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.70M |
| Shares Out | 3.71M |
| EPS (ttm) | -745.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,175 |
| Open | 2.930 |
| Previous Close | 2.950 |
| Day's Range | 2.860 - 2.990 |
| 52-Week Range | 2.810 - 485.366 |
| Beta | 5.58 |
| Analysts | Strong Buy |
| Price Target | 5,920.00 (+202,639.73%) |
| Earnings Date | Aug 7, 2025 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute mye... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for APVO stock is "Strong Buy" and the 12-month stock price target is $5,920.0.
News
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on...
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipl...
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
Aptevo More Than Doubles After Favorable Results in Leukemia Study
Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia s...
Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer
Aptevo Therapeutics Inc APVO stock is surging on Wednesday.
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro...
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine rele...
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical st...
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-on...
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology t...
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform d...
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l...
Aptevo to Participate in March Conferences
SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro...
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with A...
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% ...
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a ...
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology th...
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATT...
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a ...
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...